Frequently Asked Questions
The market is segmented based on , By Drug Type (Alcohol, Marijuana, Opioids, Cocaine, Amphetamine, Methamphetamine, Benzodiazepines and Others), Product (1- Panel Saliva Drug Test Kit, 4- Panel Saliva Drug Test Kits, 5- Panel Saliva Drug Test Kits, 6- Panel Saliva Drug Test Kits, 10- Panel Saliva Drug Test Kits and 12- Panel Saliva Drug Test Kits), By Form (Cassettes, Swabs and Strips), By Application (Criminal Justice Testing, Workplace Testing and Disease Testing), By End User (Hospitals, Diagnostic Laboratories, Forensic Laboratories, Private Employers, Home Care Settings and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028.
.
The Global Rapid Oral Fluid Screening Device Market size was valued at USD 6867.15 USD Million in 2020.
The Global Rapid Oral Fluid Screening Device Market is projected to grow at a CAGR of 15.54% during the forecast period of 2021 to 2028.
The major players operating in the market include Abbott, Thermo Fisher Scientific, Drägerwerk, Laboratory Corporation of America Holdings, Quest Diagnostics orporated, OraSure Technologies, Omega Laboratories, F. Hoffmann La Roche Ltd, Shimadzu Corporation, Oranoxis, Premier Biotech, UCP Biosciences, SCREEN ITALIA Srl, Securetec, MEDACX , AccuBioTech Co., Psychemedics Corporation, American Bio Medica Corporation.
